These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3433260)

  • 1. Properties and catabolism of heat treated antithrombin III concentrate.
    Tengborn L; Frohm B; Nilsson LE; Johansson L; Andersson LO
    Thromb Res; 1987 Dec; 48(6):701-11. PubMed ID: 3433260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombin III concentrate: its catabolism in health and in antithrombin III deficiency.
    Tengborn L; Frohm B; Nilsson LE; Nilsson IM
    Scand J Clin Lab Invest; 1981 Sep; 41(5):469-77. PubMed ID: 7031840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elimination of antithrombin III concentrate in healthy pregnant and preeclamptic women with an acquired antithrombin III deficiency.
    Weiner CP; Herrig JE; Pelzer GD; Heilskov J
    Thromb Res; 1990 May; 58(4):395-401. PubMed ID: 2353344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pasteurisation induced changes in an antithrombin III concentrate.
    Winkelman L; Haddon ME
    Thromb Res; 1986 Jul; 43(2):219-27. PubMed ID: 3738862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administration.
    Collen D; Schetz J; de Cock F; Holmer E; Verstraete M
    Eur J Clin Invest; 1977 Feb; 7(1):27-35. PubMed ID: 65284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of congenital antithrombin III deficiency with concentrates.
    Mannucci PM; Boyer C; Wolf M; Tripodi A; Larrieu MJ
    Br J Haematol; 1982 Mar; 50(3):531-5. PubMed ID: 7066204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombin III transfusion in patients with hepatic cirrhosis.
    Schipper HG; ten Cate JW
    Br J Haematol; 1982 Sep; 52(1):25-33. PubMed ID: 7115627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recovery of antithrombin III in patients undergoing orthotopic liver transplantation after administration of an antithrombin III concentrate.
    Scherer RU; Gödde S; Giebler RM; Schmutzler MJ; Erhard J; Kox WJ
    Semin Thromb Hemost; 1993; 19(3):309-10. PubMed ID: 8362259
    [No Abstract]   [Full Text] [Related]  

  • 9. Elimination of intravenously administered radiolabelled antithrombin III and heparin in humans.
    de Swart CA; Nijmeyer B; Andersson LO; Holmer E; Sixma JJ; Bouma BN
    Thromb Haemost; 1984 Aug; 52(1):66-70. PubMed ID: 6495266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group.
    Schwartz RS; Bauer KA; Rosenberg RD; Kavanaugh EJ; Davies DC; Bogdanoff DA
    Am J Med; 1989 Sep; 87(3B):53S-60S. PubMed ID: 2679072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of antithrombin III assays using biological and chromogenic substrates.
    Philo RD; Gaffney PJ
    Br J Haematol; 1982 Jan; 50(1):147-56. PubMed ID: 7055531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Cooperative Study Group.
    Menache D; O'Malley JP; Schorr JB; Wagner B; Williams C; Alving BM; Ballard JO; Goodnight SH; Hathaway WE; Hultin MB
    Blood; 1990 Jan; 75(1):33-9. PubMed ID: 2403821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of elimination of antithrombin III concentrate in heparinized patients.
    Marciniak E; Gockerman JP
    Br J Haematol; 1981 Aug; 48(4):617-25. PubMed ID: 7272219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-coagulant therapy--antithrombin III].
    Tsuji H
    Rinsho Ketsueki; 1990 Jun; 31(6):750-5. PubMed ID: 2214165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of planned pregnancy in a patient with congenital antithrombin III deficiency.
    Samson D; Stirling Y; Woolf L; Howarth D; Seghatchian MJ; de Chazal R
    Br J Haematol; 1984 Feb; 56(2):243-9. PubMed ID: 6691921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catabolism and distribution of functionally heterogeneous human antithrombin III.
    Marciniak E; Romond EH
    J Lab Clin Med; 1987 Jan; 109(1):89-96. PubMed ID: 3794520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The plasma turnover of transfused antithrombin concentrate in patients with acquired antithrombin deficiency.
    Harper PL; Park GR; Carrell RW
    Transfus Med; 1996 Mar; 6(1):45-50. PubMed ID: 8696447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Separation of active and inactive forms of human antithrombin by heparin affinity chromatography.
    Heger A; Grunert T; Schulz P; Josic D; Buchacher A
    Thromb Res; 2002 Apr; 106(2):157-64. PubMed ID: 12182916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Management with antithrombin III concentrate in a pregnant woman with hereditary antithrombin III deficiency].
    Higuchi M; Konya H; Tanaka H; Masuda H; Nishida Y; Koyama T; Suehiro A; Kakishita E; Ishita K
    Rinsho Ketsueki; 1990 Sep; 31(9):1544-7. PubMed ID: 2246830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies of the heterogeneity of antithrombin III concentrates.
    Barrowcliffe TW; Eggleton CA; Mahmoud M
    Br J Haematol; 1983 Sep; 55(1):37-46. PubMed ID: 6882687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.